Follow
Gerhardt Attard
Gerhardt Attard
University College London Cancer Institute
Verified email at ucl.ac.uk - Homepage
Title
Cited by
Cited by
Year
Integrative clinical genomics of advanced prostate cancer
D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ...
Cell 161 (5), 1215-1228, 2015
35312015
DNA-repair defects and olaparib in metastatic prostate cancer
J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ...
New England Journal of Medicine 373 (18), 1697-1708, 2015
22322015
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
The Lancet 387 (10024), 1163-1177, 2016
20302016
Abiraterone for prostate cancer not previously treated with hormone therapy
ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ...
New England Journal of Medicine 377 (4), 338-351, 2017
16962017
Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostrate cancer commonly remains hormone driven
G Attard, AH Reid, TA Yap, F Raynaud, M Dowsett
Journal of clinical oncology 26 (28), 4563-4571, 2008
10702008
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ...
The Lancet 392 (10162), 2353-2366, 2018
10352018
Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
831*2018
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
G Attard, AHM Reid, R A’Hern, C Parker, NB Oommen, E Folkerd, ...
Journal of clinical oncology: official journal of the American Society of …, 2009
7232009
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer
G Attard, JF Swennenhuis, D Olmos, AHM Reid, E Vickers, R A'Hern, ...
Cancer research 69 (7), 2912-2918, 2009
6822009
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
G Attard, J Clark, L Ambroisine, G Fisher, G Kovacs, P Flohr, D Berney, ...
Oncogene 27 (3), 253-263, 2008
5722008
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
AHM Reid, G Attard, DC Danila, NB Oommen, D Olmos, PC Fong, ...
Journal of clinical oncology 28 (9), 1489, 2010
5062010
Plasma AR and abiraterone-resistant prostate cancer
A Romanel, DG Tandefelt, V Conteduca, A Jayaram, N Casiraghi, ...
Science translational medicine 7 (312), 312re10-312re10, 2015
4422015
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y Loriot, D Bianchini, E Ileana, S Sandhu, A Patrikidou, C Pezaro, ...
Annals of oncology 24 (7), 1807-1812, 2013
4092013
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer
HI Scher, G Heller, A Molina, G Attard, DC Danila, X Jia, W Peng, ...
Journal of clinical oncology 33 (12), 1348, 2015
3982015
Tumor clone dynamics in lethal prostate cancer
S Carreira, A Romanel, J Goodall, E Grist, R Ferraldeschi, S Miranda, ...
Science translational medicine 6 (254), 254ra125-254ra125, 2014
3822014
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ...
Annals of Oncology 26 (8), 1589-1604, 2015
3782015
Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ...
Annals of Oncology 30 (12), 1992-2003, 2019
3372019
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer
AHM Reid, G Attard, L Ambroisine, G Fisher, G Kovacs, D Brewer, J Clark, ...
British journal of cancer 102 (4), 678-684, 2010
3222010
Steroid hormone receptors in prostate cancer: a hard habit to break?
G Attard, CS Cooper, JS de Bono
Cancer cell 16 (6), 458-462, 2009
3092009
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100
J Richards, AC Lim, CW Hay, AE Taylor, A Wingate, K Nowakowska, ...
Cancer research 72 (9), 2176-2182, 2012
2952012
The system can't perform the operation now. Try again later.
Articles 1–20